Patent Application Attorney Docket No. PC10805B

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: William J. Curatolo, et al. :

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: Herewith :Group Art Unit: To Be Assigned

TITLE: Method of Increasing the Bioavailability and :

Tissue Penetration of Azithromycin

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: OctoBen 17, 2003

James T. Jones

Attorney for Applicant(s)

Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

INFORMATION DISCLOSURE CITATION							ATTY. DOCKET NO. PC10805B					RIAL NO.	То		Ве	
(Use several sheets if necessary)							APPLICANT William J. Curatolo, et al.									
							FILING DATE Herewith					OUP gned	То		Ве	
						U.S	. PATEN	NT DOC	UMENTS			<u> </u>				
EXAMINER INITIAL				DOC	UMENT NUM	BER			DATE	NAME	:	CLASS	SUBCLASS	FILING IF APPRI	OPRIATE	
	US	6	0	0	4	9	2	7	21 Dec 99	Benet et al.		514	9			
	us	5	5	6	7	5	9	2	22 Oct 96	Benet e	Benet et al		7.21			
	us	5	6	1	6	5	9	3	1 April 97	Patel et al.		435 514	321			
	US	4	5	1	7	3	5	9	14 May 85	Kobrehel et al		536	7.4			
	US	4	4	7	4	7	6	8	2 Oct 84	Brigh	t	424	180			
						·ORE	IGN PAI	ENT DO	DCUMENTS	r -			<del></del>	т—		
DOCUMENT NUMBER								DATE COUNTR		RY CLASS		SUBCLASS	TRANS	LATION		
	1 1		т—	T			<del></del>							YES	NO	
	wo	9	5	2	0	9	8	0	10 Aug 95	Internatio	onal	A61K	45/06			
	wo	9	9	3	9	7	3	1_1_	12 Aug 99	Internation	onal	A61K	38/27			
	EP	0	9	2	5	7	8	9	30 June 99	EPO		A61K	31/70			
	CN	1	2	2	3	1	1	6	14 Jan 98		-				V	
	J.V	<u> </u>					<del> '-</del>		14 Jail 90			A61K	31/70		X	
								-								
			<del> </del>		<del>                                     </del>			<u> </u>								
	<u> </u>	***	<u> </u>	<u> </u>											l	
	<del></del>		ОТН	ER DOC	UMENT	'S (Inc	cluding A	uthor, T	itle, Date, Per	tinent Pa	ges, E	∃tc.)				
		Carlos	Cordon-	·Cardo, Pr	oc. Natl. A	cad. So	ci, 86, 1989	9, 695-698	3	-			_			
		Shiyin	Shiyin Yee, Pharmaceutical Research, vol. 14, no. 6, 1997, pgs 763-766													
			Database WPI Section Ch. Week 199947, Derwent Pub. AN 1999-551717 (XP 002171386)													
									333-331717 (XI U	02171300)						
	<del></del>		Amsden, et al., J. Clin Pharmacol, 2000, 40, pgs 1522-1527													
	+	Oleske	Oleske, Pediatrics, vol. 102, no. 4 II, 1998, pgs 1005-1062													
		-														
<u> </u>																
EXAMINE	R							DATE C	ONSIDERED							